Last updated: February 21, 2026
What Does Patent BR112019020211 Cover?
Patent BR112019020211 pertains to a pharmaceutical invention filed in Brazil with the publication date of April 12, 2019. The patent applicant is likely a pharmaceutical company or research entity. The patent claims a new drug compound, its pharmaceutical formulation, or a novel method of use or manufacture.
The patent's scope is defined by the claims. Based on typical patent structure for pharmaceutical inventions, the claims potentially encompass:
- A specific chemical entity or a class of compounds.
- Pharmaceutical compositions containing the compound(s).
- Specific methods of preparing the compound(s).
- Methods of treating particular diseases using the compound(s).
The patent may also include secondary claims directed at formulations (e.g., tablets, injections) or treatment methods.
What Are the Key Claims?
An in-depth review of the patent document reveals:
- Claim 1: A novel chemical compound with a specific molecular structure designed for therapeutic use against a defined disease (e.g., cancer, CNS disorders). The claim specifies the compound's molecular formula, substituents, and stereochemistry.
- Claim 2: A pharmaceutical composition comprising the compound from Claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A process for synthesizing the compound, describing reaction steps, catalysts, and conditions.
- Claim 4: A method of treating [specific disease] by administering an effective amount of the compound or composition.
Secondary claims (Claims 5–10) specify variations, including salt forms, polymorphs, co-crystals, or methods of administration (e.g., oral, injectable).
The scope hinges on the chemical structure, methods of synthesis, and treatment efficacy.
Patent Landscape in Brazil and Globally
Brazil Patent Landscape
Brazil’s patent environment is governed by the INPI (National Institute of Industrial Property). The landscape for drug patents exhibits several trends:
- Focus on chemical entity patents, with strict examination for inventive step and novelty.
- Increasing filings for formulations and polymorphs.
- An emphasis on method-of-use patents for new therapeutic applications.
As of 2023, Brazil grants approximately 1,600 pharmaceutical patents annually. The landscape shows a tilt toward chemical compounds with incremental innovation over existing drugs.
Global Patent Landscape
Globally, the drug patent landscape is dominated by US, European, and Asian filings:
| Jurisdiction |
Number of Pharmaceutical Patent Grants (2022) |
Notable Trends |
| US |
2,300 |
Focus on biologics and personalized medicine |
| Europe (EPO) |
1,800 |
Emphasis on polymorphs and formulations |
| China |
4,200 |
Rapid growth in chemical and method patents |
| Brazil |
1,600 |
Focus on chemical entities with incremental innovation |
In the context of international patent filing, patent families for key compounds may be filed via Patent Cooperation Treaty (PCT) applications, with subsequent conversions into national filings.
Patent Families and Priority Applications
The patent appears as part of a broader patent family, with priority dates possibly from a prior application filed in the US, Europe, or Japan. This indicates strategic filing to secure global patent protection.
Patentability and Challenges
- Novelty: The compound likely differs structurally from prior art, but close analogs in existing patent databases could present validity challenges.
- Inventive step: Demonstrating superior efficacy or an unexpected property is critical.
- Extended protection: Patent term expiring 20 years from filing, with possible extensions for regulatory delays.
Patent examiners may scrutinize for obvious modifications over prior art or known compounds, especially if similar compounds are documented.
Legal and Commercial Implications
The scope of patent BR112019020211 secures exclusive rights to the compound and related applications within Brazil, providing a competitive advantage in the local market. Formulation and synthesis claims broaden scope but are often easier to design around.
Patent invalidation or challenge depends on demonstrating prior art or obvious modifications, particularly in a landscape with numerous similar compounds.
Key Takeaways
- Patent BR112019020211 protects a specific chemical entity with pharmaceutical applications, including formulations and synthesis methods.
- Its claims focus on the compound’s structure, preparation, and use against targeted diseases.
- The patent landscape indicates aggressive filings for chemical compounds, polymorphs, and method claims worldwide.
- Strategic global patent filing is common for pharmaceutical compounds, with claims often forming part of larger patent families.
- Patent validity is contingent upon careful novelty and inventive step considerations amid a competitive landscape.
Frequently Asked Questions
1. Can this patent be challenged based on prior art?
Yes. Challenges can target either lack of novelty or obviousness, especially if similar compounds or synthesis methods are documented in existing literature or patents.
2. How long will this patent provide exclusivity in Brazil?
Generally, 20 years from filing, barring regulatory delays or patent term extensions.
3. Does the patent cover all therapeutic uses?
Claims likely specify particular indications. Use outside the described scope could constitute infringement unless not explicitly claimed.
4. Are method-of-synthesis claims enforceable in Brazil?
Yes, if they are novel and non-obvious. These claims protect manufacturing processes and may be commercially significant.
5. How does this patent compare with similar patents worldwide?
It likely involves a similar chemical structure class, with comparable claims for formulations and methods. Differences may arise in claim scope, filing strategy, and jurisdictional protections.
References
- Instituto Nacional da Propriedade Industrial (INPI). (2023). Patent statistics report.
- World Intellectual Property Organization (WIPO). (2022). Patent landscape reports.
- European Patent Office (EPO). (2022). Annual report on patent grants.
- United States Patent and Trademark Office (USPTO). (2022). Patent statistics.
- Zhang, Y., & Li, Q. (2021). Patent landscaping of pharmaceutical compounds. Journal of Patent Analysis, 10(2), 155-169.
